Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Acta Histochem ; 113(8): 815-25, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21774970

ABSTRACT

The aim of the study was to investigate the content and distribution of sugar residues in placentas from pregnancies complicated by hypertensive disorders. Placentas from women with uncomplicated pregnancies (group 1), pregnancies complicated by gestational hypertension (group 2), pregnancies complicated by pre-eclampsia (group 3), pregnancies complicated by pre-eclampsia with HELLP syndrome (hemolysis, elevated liver enzymes and low platelets) (group 4) were collected. Lectins: ConA, WGA, PNA, SBA, DBA, UEA I, GNA, DSA, MAA, SNA, in combination with chemical and enzymatic treatments, were used. Data showed a decrease and/or lack of α-d-mannose, α-d-glucose and d-galactose-(ß1-4)-N-acetyl-d-glucosamine in placentas from pre-eclampsia and pre-eclampsia with HELLP syndrome compared with control and hypertension cases. N-acetyl-d-galactosamine appeared and/or increased in placentas from hypertensive disorders. A different distribution of various types of sialic acid was observed in placentas from hypertensive disorders compared with the controls. In particular, placentas from pre-eclampsia, with and without HELLP syndrome, lacked the acetylated sialic acid side-chain. These findings demonstrate various alterations of the carbohydrate metabolism in the placentas from pregnancies complicated by different types of hypertensive disorders. This indicates correlation with the placental morpho-functional changes characteristic of these complications and with the degree of clinical severity.


Subject(s)
Carbohydrates/analysis , HELLP Syndrome/metabolism , Placenta/metabolism , Pre-Eclampsia/metabolism , Pregnancy/metabolism , Acetylgalactosamine/analysis , Acetylgalactosamine/metabolism , Acetylglucosamine/analysis , Acetylglucosamine/metabolism , Adult , Carbohydrates/chemistry , Disease Progression , Female , Galactose/analysis , Galactose/metabolism , Glucose/analysis , Glucose/metabolism , HELLP Syndrome/pathology , HELLP Syndrome/physiopathology , Humans , Lectins , Mannose/analysis , Mannose/metabolism , Placenta/physiopathology , Pre-Eclampsia/pathology , Pre-Eclampsia/physiopathology
2.
Am J Physiol Endocrinol Metab ; 301(1): E25-30, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21467301

ABSTRACT

The "Barker hypothesis" suggests that low birth weight might predict future risk of developing obesity, cardiovascular disease, and type 2 diabetes. Identification of the causes of fetal growth restriction (FGR) is critical for preventive and management strategies. Some studies indicate that maternal carbohydrate metabolism might be involved in FGR development. We aimed to evaluate, in a large number of normotensive pregnant women with normal glucose tolerance, the effect of insulin sensitivity and ß-cell function on unexplained fetal growth. A total of 1,814 Caucasian pregnant women with normal prepregnancy body mass index were tested with a 75-g, 2-h glucose load (24-28 gestation wk). Insulin sensitivity was evaluated with fasting (QUICKI) and dynamic index (OGIS) and ß-cell function with a modified insulinogenic index as ΔAUC(insulin)/ΔAUC(glucose) and disposition index. FGR was a birth weight below the 5th percentile for gestational age. FGR developed in 99 (5.5%) pregnant women that showed significantly higher QUICKI, OGIS, insulinogenic, and disposition index with respect to women with normal-weight babies (P < 0.0001). By using multiple regression analysis in the FRG group, QUICKI and OGIS appeared as significant independent variables (P < 0.0001 and P < 0.0366, respectively). We conclude that elevated insulin sensitivity seems to be one of the factors involved in determining unexplained fetal growth retardation; its assessment, even only in the fasting state, could be useful to guide any possible monitoring and therapeutic strategies to reduce fetal complications.


Subject(s)
Fetal Growth Retardation/metabolism , Infant, Low Birth Weight , Insulin Resistance , Insulin-Secreting Cells/physiology , Mothers , Adult , Blood Glucose/analysis , Blood Glucose/metabolism , Case-Control Studies , Female , Fetal Growth Retardation/diagnosis , Fetal Growth Retardation/etiology , Glucose Tolerance Test , Humans , Infant, Low Birth Weight/metabolism , Infant, Low Birth Weight/physiology , Infant, Newborn/growth & development , Insulin/blood , Insulin/metabolism , Insulin/pharmacology , Insulin Resistance/physiology , Pregnancy , Prognosis , Up-Regulation
3.
Eur J Obstet Gynecol Reprod Biol ; 145(2): 149-53, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19467766

ABSTRACT

OBJECTIVE: This prospective study evaluated the impact of gestational diabetes on maternal and fetal outcome in a large cohort of women with gestational diabetes mellitus (GDM) followed up using standardized clinical criteria. STUDY DESIGN: Between 1999 and 2003, we collected 3465 GDM women from 31 Italian regional obstetric or diabetes centers, recording the time and mode of delivery, gestational hypertension, pre-eclampsia, eclampsia, congenital malformations, and neonatal mortality, comparing findings with the Italian general pregnant population. RESULTS: The rate of cesarean sections was 34.9% and macrosomia 8.7% (33.2 and 7.4%, respectively, in the general population, p=ns). The stillbirth and neonatal mortality rates were no different in GDM patients and normal pregnancies (0.34% vs. 0.30%, p=0.176 and 0.29% vs. 0.32%, p=0.748), but the former had twice as many newborn with congenital malformations (2.05% vs. 0.89%, p<0.01; CI 1.64-2.62). A prognostic model for the outcome of pregnancy was built and the concurrent occurrence of several conditions was deemed as a positive outcome. Pregnancies which did not meet one or more of the above criteria were classified as "complicated". On multivariate logistic analysis, only the week of gestation when GDM was diagnosed and prepregnancy BMI were independent predictors of a complicated pregnancy. CONCLUSION: When correctly diagnosed and treated during pregnancy, women with GDM have a pregnancy outcome similar to the general pregnant population, except for a greater likelihood of congenital malformations in the newborn, probably due to unrecognized prior diabetes. Prepregnancy obesity plays an important part in raising the risk of adverse perinatal outcomes in GDM patients.


Subject(s)
Diabetes, Gestational/diagnosis , Pregnancy Outcome , Cesarean Section/statistics & numerical data , Congenital Abnormalities/epidemiology , Diabetes, Gestational/epidemiology , Female , Fetal Macrosomia/epidemiology , Humans , Italy/epidemiology , Obesity/complications , Pregnancy
4.
Nutr Metab Cardiovasc Dis ; 18(4): 291-7, 2008 May.
Article in English | MEDLINE | ID: mdl-17433638

ABSTRACT

BACKGROUND AND AIM: To determine pregnancy outcome in women with type 1 and type 2 diabetes. METHODS AND RESULTS: A prospective study was conducted in 33 centers in Italy between 1999 and 2003, mainly recording preterm delivery, stillbirths, neonatal mortality, congenital malformations and birthweight. Of the 668 women examined, 504 had type 1 diabetes and 164 had type 2. Pre-pregnancy counseling had been provided to 43.9% of the women who had type 1 diabetes and 29.1% of the women who had type 2 diabetes and correlated with a better HbA1c value throughout pregnancy. The preterm delivery rate was significantly higher in type 1 and 2 diabetics than in normal pregnant women and was related to HbA1c values higher than 8%, gestational hypertension, pre-eclampsia and the presence of retinopathy before pregnancy. The stillbirth and neonatal mortality rates were also higher in diabetic pregnant women (1.26% and 0.63%, respectively) than in Italian pregnancies in general (0.30% and 0.32%), and the same was true for major congenital malformations (4.9% for diabetic pregnancies, 0.86% for normal Italian pregnancies). CONCLUSIONS: In our population, pregnancy in diabetic women was still associated with a high rate of stillbirths, neonatal mortality and congenital malformations. Unplanned pregnancies and non-optimal glycemia control may help explain the high rates of maternal and neonatal complications.


Subject(s)
Diabetes Mellitus, Type 1/physiopathology , Diabetes Mellitus, Type 2/physiopathology , Pregnancy Outcome , Pregnancy in Diabetics/physiopathology , Adult , Birth Weight , Congenital Abnormalities/epidemiology , Female , Glycated Hemoglobin/metabolism , Humans , Infant Mortality , Infant, Newborn , Italy/epidemiology , Obstetric Labor, Premature/epidemiology , Pregnancy , Prospective Studies , Risk Factors , Stillbirth/epidemiology
5.
Histochem Cell Biol ; 128(3): 263-73, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17653755

ABSTRACT

The aim of this study was to investigate the distribution of the oligosaccharides of the glycoconjugates in placentas from pregnancies complicated by different degree of altered glycaemia. Placentas from women with physiological pregnancies (group 1), with pregnancies complicated by minor degree of glucose intolerance (group 2) and with pregnancies complicated by gestational diabetes mellitus (GDM) treated with insulin (group 3) were collected. Ten lectins were used (ConA, WGA, PNA, SBA, DBA, LTA, UEA I, GSL II, MAL II and SNA) in combination with chemical and enzymatic treatments. The data showed a decrease of sialic acid linked alpha(2-6) to galactose/N-acetyl-D-galactosamine and an increase of N-acetyl-D-glucosamine in the placentas of the pathological groups, in particular the group 3, comparing to the group 1. A decrease of L-fucose (LTA) and D-galactose-(beta1-3)-N-acetyl-D-galactosamine, and an increase and/or appearance of L-fucose (UEA I) and N-acetyl-D-galactosamine were observed in both the pathological groups, particularly in the group 2, with respect to the group 1. In GDM, and even in pregnancies with a simple alteration of maternal glycaemia, the changes in the distribution of oligosaccharides could be related to alteration of the structure and functionality of the placenta.


Subject(s)
Diabetes, Gestational/metabolism , Glycoconjugates/analysis , Lectins/analysis , Oligosaccharides/analysis , Placenta/chemistry , Pregnancy Complications , Adult , Diabetes, Gestational/pathology , Female , Glucose Tolerance Test , Glycoconjugates/pharmacokinetics , Horseradish Peroxidase/chemistry , Humans , Immunohistochemistry , Lectins/pharmacokinetics , Oligosaccharides/pharmacokinetics , Placenta/metabolism , Placenta/pathology , Pregnancy , Tissue Distribution , Umbilical Cord/metabolism
6.
Eur J Obstet Gynecol Reprod Biol ; 130(1): 30-41, 2007 Jan.
Article in English | MEDLINE | ID: mdl-16442695

ABSTRACT

OBJECTIVE: Content and distribution of the oligosaccharides in the umbilical cord from pregnancies with altered glycemia were investigated. STUDY DESIGN: A prospective cohort study was conducted in the Florence Policlinic of Careggi, Italy. Samples of cord from physiological pregnancies (n=20), from pregnancies with minor degree of glucose intolerance (n=20) and from pregnancies with gestational diabetes mellitus (GDM) treated with insulin (n=20) were collected. Eleven lectins were used (ConA, WGA, PNA, SBA, DBA, LTA, UEA I, OOA, GSL II, MAL II and SNA) in combination with chemical and enzymatic treatments. RESULTS: Increase of N-acetyl-d-glucosamine and a loss of sialic acid in the umbilical cord of the cases with minor degree of glucose intolerance with respect to the other study groups was observed. d-Galactose(beta1-->3)-N-acetyl-d-galactosamine, N-acetyl-d-galactosamine and l-fucose were in less amount in both the pathological groups with respect to the control one. CONCLUSION: The increase of some glycoconjugates carbohydrates and the loss of others in the umbilical cord from pregnancies with minor degree of glucose intolerance might be related to its morphofunctional alterations in a not diabetic altered glycemia. Moreover, the treatment with insulin in the GDM might play a role in restoring partially the normal glycosilation in the cord components in the attempt to renew some their functions.


Subject(s)
Diabetes, Gestational/physiopathology , Glycoconjugates/metabolism , Lectins/metabolism , Umbilical Cord/metabolism , Adult , Cohort Studies , Diabetes, Gestational/metabolism , Female , Glycoconjugates/analysis , Humans , Immunohistochemistry , Lectins/analysis , Pregnancy , Prospective Studies
7.
J Hypertens ; 24(9): 1823-9, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16915032

ABSTRACT

OBJECTIVES: Pre-eclampsia is associated with vascular endothelial dysfunction, adverse pregnancy outcome and cardiovascular disease in later life. An inadequate nitric oxide availability related to polymorphisms in the endothelial nitric oxide synthase gene (eNOS) might predispose to the disease. METHODS: We investigated the role of eNOS T-786C, G894T and 4a4b polymorphisms in predisposing to both pre-eclampsia and the recurrence of negative pregnancy events, per se and in the presence of angiotensin-converting enzyme (ACE) DD genotype, and investigated their influence on maternal-fetal flow in 106 non-thrombophilic women with a history of pre-eclampsia, compared with 106 women with a history of normal pregnancy. RESULTS: No association between eNOS polymorphisms and predisposition to pre-eclampsia was found; nevertheless, the contemporary presence of eNOS 894TT and -786CC genotypes represented a susceptibility factor to the disease. In 48 out of 106 women, documented complications (pre-eclampsia and fetal growth restriction) were present in the current pregnancy. The eNOS 894TT genotype influenced the risk of recurrence of negative events (odds ratio = 5.45), particularly in contemporary women homozygous for both eNOS 894TT and ACE DD genotypes (odds ratio = 11.4). Throughout the pregnancy, a progressive alteration of maternal-fetal flow indices was found in women carrying the eNOS 894TT genotype, and this effect was strengthened in women with the contemporary presence of the ACE DD genotype. CONCLUSIONS: An original finding is the increased risk of pre-eclampsia and recurrence of pregnancy negative events, probably by modulating the maternal-fetal flow, in women homozygous for the eNOS 894T allele previously analyzed for the ACE I/D polymorphism.


Subject(s)
Gene Expression Regulation, Enzymologic , Nitric Oxide Synthase Type III/genetics , Nitric Oxide Synthase Type III/physiology , Polymorphism, Genetic , Pre-Eclampsia/diagnosis , Adult , Alleles , Female , Genetic Predisposition to Disease , Genotype , Humans , Maternal-Fetal Exchange , Odds Ratio , Peptidyl-Dipeptidase A/genetics , Pre-Eclampsia/pathology , Pregnancy , Pregnancy Outcome , Recurrence , Thrombophilia/genetics
8.
Hypertension ; 47(3): 449-53, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16446386

ABSTRACT

Certain similarities between preeclampsia and insulin resistance syndrome suggest a possible link between the 2 diseases. The aim of our study was to evaluate 3 insulin sensitivity (IS) indexes (fasting homeostasis model assessment IS [ISHOMA], quantitative insulin sensitivity check index [ISQUICKI], and oral glucose IS [OGIS]) early and late in pregnancy in a large number of normotensive pregnant women with a normal glucose tolerance and to test the ability of these indexes to predict the risk of subsequent preeclampsia. In all, 829 pregnant women were tested with a 75-g, 2-hour oral glucose load in 2 periods of pregnancy: early (16 to 20 weeks) and late (26 to 30 weeks). In early and late pregnancy, respectively, IS(HOMA) was 1.23+/-0.05 and 1.44+/-0.05 (P<0.01), IS(QUICKI) was 0.40+/-0.002 and 0.38+/-0.002 (P<0.01), and OGIS was 457+/-2.4 mL min(-1) m(-2) and 445+/-2.2 (P<0.001), all confirming the reduction in insulin sensitivity during pregnancy. Preeclampsia developed in 6.4% of the pregnant women and correlated positively with the 75th centile of IS(HOMA) (P=0.001), with a sensitivity of 79% in the early and 83% in the late period and a specificity of 97% in both. IS(QUICKI) <25th centile was also related with preeclampsia (P=0.001), with a sensitivity of 85% in the early and 88% in the late period and a specificity of 97% in both. Judging from our findings, ISHOMA and ISQUICKI are simple tests that can pinpoint impaired insulin sensitivity early in the pregnancy. Given their high sensitivity and specificity, these indexes could be useful in predicting the development of preeclampsia in early pregnancy, before the disease become clinically evident.


Subject(s)
Blood Glucose/metabolism , Insulin Resistance , Pre-Eclampsia/etiology , Pregnancy/metabolism , Thinness , Adult , Fasting/blood , Female , Glucose/pharmacology , Glucose Tolerance Test , Homeostasis , Humans , Incidence , Pre-Eclampsia/epidemiology , Predictive Value of Tests , Pregnancy Trimester, First , Pregnancy Trimester, Second , Risk Assessment
9.
Hypertension ; 46(6): 1270-4, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16246971

ABSTRACT

The role of thrombophilia in the pathogenesis of preeclampsia is controversial. The aim of this case-controlled study was to determine whether thrombophilia increases the risk of preeclampsia or interferes with its clinical course. A total of 808 white patients who developed preeclampsia (cases) and 808 women with previous uneventful pregnancies (controls) matched for age and parity were evaluated for inherited and acquired thrombophilia (factor V Leiden; factor II G20210A; methylenetetrahydrofolate reductase C677T; protein S, protein C, and antithrombin III deficiency; anticardiolipin antibodies; lupus anticoagulant; and hyperhomocysteinemia). Odds ratios (ORs) with 95% confidence intervals (CIs) for risk of being carriers of thrombophilia in cases compared with controls and for risk of maternal life-threatening complications and adverse perinatal outcomes in preeclamptic patients with or without thrombophilia were calculated. Women with severe preeclampsia (406 cases) had a higher risk (OR, 4.9; 95% CI, 3.5 to 6.9) of being carriers of either an inherited or acquired thrombophilic factor, except for protein S, protein C, and antithrombin deficiency. In women with mild preeclampsia (402 cases), only prothrombin and homozygous methylenetetrahydrofolate reductase gene mutations were significantly more prevalent than in the controls. Thrombophilic patients with severe preeclampsia are at increased risk of acute renal failure (OR, 1.8; 95% CI, 1.5 to 2.2), disseminated intravascular coagulation (OR, 2.7; 95% CI, 1.1 to 6.4), abruptio placentae (OR, 2.6; 95% CI, 1.2 to 6.0) and perinatal mortality (OR, 1.7; 95% CI, 1.5 to 2.2) compared with nonthrombophilic preeclamptic patients. Our study demonstrates a significant association between maternal thrombophilia and severe preeclampsia in white women. Thrombophilia also augments the risk of life-threatening maternal complications and adverse perinatal outcomes in preeclamptic patients.


Subject(s)
Pre-Eclampsia , Thrombophilia/complications , Case-Control Studies , Female , Heterozygote , Humans , Pre-Eclampsia/physiopathology , Pregnancy , Pregnancy Outcome , Risk Assessment , Severity of Illness Index , Thrombophilia/etiology , Thrombophilia/genetics
10.
Hypertension ; 45(1): 86-91, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15557391

ABSTRACT

Data from literature report that angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism affects the recurrence of preeclampsia and that low-molecular-weight heparin (LMWH) prevents adverse outcomes in thrombophilic women. We investigated the effect of LMWH on the pregnancy outcome, on maternal blood pressure values, and on uteroplacental flow in ACE DD nonthrombophilic women with history of preeclampsia. Eighty nonthrombophilic ACE DD women were randomized in 2 groups: 41 treated with dalteparin 5000 IU/day and 39 untreated (control group). Women underwent 24-hour automated blood pressure monitoring in the preconceptional period and every 2 weeks from weeks 8 to 36 and transabdominal color flow/pulsed Doppler examination at weeks 16, 20, and 24. LMWH reduced the risk of clinical negative outcomes (74.1% reduction of preeclampsia and 77.5% reduction of fetal growth restriction) and the severity (88.3% reduction of early onset of preeclampsia and 86.4% reduction of early onset of fetal growth restriction). In treated women, the relative risk for preeclampsia was 0.26 (P=0.02), and the relative risk for fetal growth restriction was 0.14 (P<0.001). Systolic (P=0.002) and diastolic (P=0.002) blood pressures, as well as awake (P=0.04) and asleep (P=0.01) period values, and the resistance indexes of both uterine arteries (P=0.002) were lower in the treated group. LMWH reduces the recurrence of preeclampsia, of negative outcomes, and the resistance of uteroplacental flow, and also prevents maternal blood pressure increase in ACE DD homozygote women with a previous history of preeclampsia.


Subject(s)
Anticoagulants/therapeutic use , Dalteparin/therapeutic use , Heparin, Low-Molecular-Weight/therapeutic use , Peptidyl-Dipeptidase A/genetics , Pre-Eclampsia/prevention & control , Adult , Birth Weight , Circadian Rhythm , Diastole/drug effects , Female , Fetal Growth Retardation/diagnostic imaging , Fetal Growth Retardation/epidemiology , Fetal Growth Retardation/prevention & control , Genetic Predisposition to Disease , Homozygote , Humans , Infant, Newborn , Placental Circulation/drug effects , Pre-Eclampsia/enzymology , Pre-Eclampsia/epidemiology , Pre-Eclampsia/genetics , Pregnancy , Pregnancy Outcome , Recurrence , Risk , Sequence Deletion , Systole/drug effects , Treatment Outcome , Ultrasonography, Doppler, Color , Ultrasonography, Doppler, Pulsed , Ultrasonography, Prenatal , Uterus/blood supply , Vascular Resistance/drug effects
11.
BJOG ; 111(6): 564-70, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15198784

ABSTRACT

OBJECTIVE: To determine the expression of VEGF in the placental tissue from pregnancies complicated by hypertension disorders of different clinical severity. DESIGN: Prospective cohort study. SETTING: Polyclinic of Careggi, University of Florence, Italy. SAMPLE: Placentas from women with gestational hypertension (n= 20), pre-eclampsia (n= 20) and pre-eclampsia with HELLP syndrome (n= 20) and from normotensive women (n= 20), as control group (gestational age comprised between 35 and 38 weeks). METHODS: An immunohistochemical technique and a quantitative analysis to measure mRNA levels (RT-PCR) were employed. MAIN OUTCOME MEASURES: Intensity of immunoreactivity and mRNA levels in the placental components. Differences between the data. RESULTS: VEGF immunoreactivity was observable in all the placental components in the gestational hypertension cases as in the control ones. In the cases with pre-eclampsia and pre-eclampsia with HELLP syndrome, some placental components were not immunoreactive. However, the VEGF positive components of all the pathological groups showed a higher intensity of reactivity with respect to that of the control group. The levels of VEGF mRNA were higher in the gestational hypertension cases and lower in the cases of pre-eclampsia with HELLP syndrome with respect to the control ones; in the cases of pre-eclampsia, the levels were the same as the control ones. CONCLUSION: The different expression of VEGF in the placenta of the pathological cases is probably related to haemodynamic changes that take place in these disorders, in order to attempt restoration of a normal uteroplacental flow.


Subject(s)
Hypertension/metabolism , Placenta/metabolism , Pregnancy Complications, Cardiovascular/metabolism , Vascular Endothelial Growth Factor A/metabolism , Adult , Cohort Studies , Female , HELLP Syndrome/metabolism , Humans , Pre-Eclampsia/metabolism , Pregnancy , Prospective Studies , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction/methods
12.
Eur J Obstet Gynecol Reprod Biol ; 111(1): 19-24, 2003 Nov 10.
Article in English | MEDLINE | ID: mdl-14557006

ABSTRACT

OBJECTIVE: To compare maternal glucose levels and neonatal outcome, achieved in women with gestational diabetes (GDM) receiving either regular insulin or insulin lispro, with those of a control group of non-diabetic pregnant women. STUDY DESIGN: We enrolled 49 pregnant women with GDM, randomly allocated to the treatment with either insulin lispro (n=25) or regular insulin (n=24), and 50 pregnant women with normal GCT, matched for age, parity, pre-pregnancy weight and BMI, who formed the control group. All the women were caucasian, non-obese, with a singleton pregnancy and delivered term live born infants. Women of both groups were requested to perform a blood glucose profile (consisting of nine determinations: fasting/pre-prandial, 1 and 2h post-prandial) every week from the time of diagnosis to 38 weeks (study subgroups) or every 2 weeks from 28 to 38 weeks' gestation (control group). RESULTS: Overall pre-prandial blood glucose values in diabetic women were significantly higher than those of controls; at the 1h post-prandial time point, blood glucose values of GDM women receiving insulin lispro were similar to those of controls, whereas in the regular group they were significantly higher. Overall, both the lispro and regular insulin obtained optimal metabolic control at the 2h post-prandial time point, although near-normal blood glucose levels 2h after lunch could be observed only in the lispro group. There were no statistically significant differences between the groups in neonatal outcome and anthropometric characteristics; however, the rate of infants with a cranial-thoracic circumference (CC/CT) ratio between the 10th and the 25th percentile was significantly higher in the group treated with regular insulin in comparison to the lispro and control groups. CONCLUSIONS: Fasting/pre-prandial and 1h post-prandial maternal blood glucose levels in non-diabetic pregnant women fell well below the currently accepted criteria of glycemic normality in diabetic pregnancies. In women with GDM, the use of insulin lispro enabled the attainment of near-normal glucose levels at the 1h post-prandial time point and was associated with normal anthropometric characteristics; the use of regular insulin was not able to blunt the 1h peak post-prandial response to a near-normal extent and resulted in infants with a tendency toward the disproportionate growth. Insulin lispro can be regarded as a valuable option for the treatment of gestational diabetes.


Subject(s)
Diabetes, Gestational/drug therapy , Diabetes, Gestational/metabolism , Hypoglycemic Agents/therapeutic use , Insulin/analogs & derivatives , Insulin/therapeutic use , Pregnancy Outcome , Adult , Birth Weight , Blood Glucose/analysis , Fasting , Female , Gestational Age , Humans , Infant, Newborn , Insulin Lispro , Pregnancy , Reference Values , Skull/anatomy & histology , Skull/growth & development , Thorax/anatomy & histology , Thorax/growth & development
13.
Diabetes Care ; 26(10): 2741-8, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14514573

ABSTRACT

OBJECTIVE: To investigate the maternal demographic and metabolic factors contributing to the growth of fetal lean and fat body mass in women whose degree of glucose intolerance is less than that defining gestational diabetes in comparison with women with normal glucose metabolism. RESEARCH DESIGN AND METHODS: Longitudinal sonographic examinations of 66 singleton fetuses without anomalies of nonobese mothers with abnormal oral glucose challenge test (GCT) results and without gestational diabetes (group 1) were compared with those of 123 singleton fetuses without anomalies of nonobese mothers with normal GCT values (group 2). Lean body mass measurements included head circumference, femur length, mid-upper arm, and mid-thigh central areas. Fat body mass measurements included the anterior abdominal wall thickness, the subscapular thickness, and the mid-upper arm and mid-thigh subcutaneous areas. All the women performed a 24-h glucose profile on the day preceding the ultrasound scan. Multivariate logistic regression analysis established best-fit equations for fetal sonographic measurements of fat and lean body mass. Independent variables included groups 1 and 2, maternal age, parity, prepregnancy BMI, gestational age, weight gain during pregnancy, fetal sex, and the following averaged 24-h profile maternal capillary blood glucose values: preprandial, 1-h postprandial, and 2-h postprandial. RESULTS: No difference was found between the two groups with respect to fetal lean body mass parameters; the factors that contributed significantly and most frequently were gestational age and fetal sex (male). With respect to fetal fat body mass, all the measurements were significantly higher in group 1 than in group 2. In all instances, the significantly contributing factors were gestational age and maternal 1-h postprandial glucose values, whereas another frequent contributor was prepregnancy BMI. CONCLUSIONS: Our study suggests the possibility of using sonographically determined fetal fat and lean mass measurements as indicators of body composition. The assessment of these parameters, achievable in a noninvasive and reproducible fashion in pregnancies complicated by glucose intolerance, might enable the real-time detection of fetal overgrowth and disproportion, thus opening the possibility of exploring interventions to limit fetal fat accretion, birth weight, and potential resulting morbidity.


Subject(s)
Body Composition , Diabetes, Gestational/metabolism , Embryonic and Fetal Development , Glucose/metabolism , Ultrasonography, Prenatal , Adult , Diabetes, Gestational/diagnostic imaging , Female , Fetal Macrosomia/diagnostic imaging , Fetal Macrosomia/metabolism , Gestational Age , Glucose Intolerance/diagnostic imaging , Glucose Intolerance/metabolism , Humans , Longitudinal Studies , Male , Pregnancy
14.
Diabetes Care ; 26(4): 1206-10, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12663598

ABSTRACT

OBJECTIVE: To investigate, in pregnant women without gestational diabetes mellitus (GDM), the relation among obstetric/demographic characteristics; fasting, 1-h, and 2-h plasma glucose values resulting from a 75-g glucose load; and the risk of abnormal neonatal anthropometric features and then to verify the presence of a threshold glucose value for a 75-g glucose load above which there is an increased risk for abnormal neonatal anthropometric characteristics. RESEARCH DESIGN AND METHODS: The study group consisted of 829 Caucasian pregnant women with singleton pregnancy who had no history of pregestational diabetes or GDM, who were tested for GDM with a 75-g, 2-h glucose load, used as a glucose challenge test, in two periods of pregnancy (early, 16-20 weeks; late, 26-30 weeks), and who did not meet the criteria for a GDM diagnosis. In the newborns, the following abnormal anthropometric characteristics were considered as outcome measures: cranial/thoracic circumference (CC/TC) ratio /=90th percentile for GA, and macrosomia (birth weight >/=90th percentile for GA), on the basis of growth standard development for our population. For the first part of the objective, logistic regression models were used to identify 75-g glucose load values as well as obstetric and demographic variables as markers for abnormal neonatal anthropometric characteristics. For the second part, the receiver operating characteristic (ROC) curve was performed for the 75-g glucose load values to determine the plasma glucose threshold value that yielded the highest combined sensitivity and specificity for the prediction of abnormal neonatal anthropometric characteristics. RESULTS: In both early and late periods, maternal age >35 years was a predictor of neonatal CC/TC ratio 35 years being an independent predictor for macrosomia. The 2-h, 75-g glucose load values were significantly associated in both periods with neonatal CC/TC ratio /=90th percentile, whereas maternal age >35 years was an independent predictor of both neonatal CC/TC ratio

Subject(s)
Blood Glucose/metabolism , Body Mass Index , Glucose Tolerance Test , Pregnancy/blood , Body Constitution , Demography , Female , Fetal Macrosomia/epidemiology , Humans , Infant, Newborn , Italy , Likelihood Functions , Male , Maternal Age , Models, Biological , Parity , Predictive Value of Tests , ROC Curve , Regression Analysis , Risk Factors , White People
15.
Hypertension ; 41(4): 932-7, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12654717

ABSTRACT

The risk for an adverse pregnancy outcome is markedly higher in women with history of preeclampsia. This may stem from impaired placentation in early gestation and from high impedance to flow in uteroplacental circulation. The renin-angiotensin system is one of the mediators of the remodeling of spiral arteries throughout pregnancy. The D allele of the Insertion/Deletion (I/D) polymorphism in the ACE gene has been associated with higher ACE activity, accounting for 47% of the total phenotypic variance of serum enzyme levels. To investigate whether the ACE I/D polymorphism affects maternal uteroplacental and fetal umbilical circulation and the pregnancy outcome in women with a history of preeclampsia, 106 women underwent Doppler examination of uterine arteries resistance index and umbilical artery pulsatility index at the 16th, 20th, and 24th weeks of gestation and were genotyped for the I/D polymorphism. This study found a difference in genotype distribution (P=0.0002) and allele frequency (P<0.0001) between women with and those without preeclampsia recurrence and fetal growth restriction as well as an association (P=0.0007) between DD genotype and risk of recurrent preeclampsia or fetal growth restriction. At the 16th, 20th, and 24th weeks, uterine artery resistance indexes were significantly lower in II, higher in DD, and intermediate in ID genotype carriers, whereas the umbilical artery pulsatility index values were significantly higher in the DD group in comparison to ID and II genotypes. The current study shows that the ACE I/D polymorphism affects uteroplacental and umbilical flows and the recurrence of an adverse pregnancy outcome in women with history of preeclampsia.


Subject(s)
Peptidyl-Dipeptidase A/genetics , Placental Circulation , Polymorphism, Genetic , Pre-Eclampsia/genetics , Adult , Female , Fetus/blood supply , Gene Frequency , Humans , Pre-Eclampsia/diagnosis , Pre-Eclampsia/physiopathology , Pregnancy , Pregnancy Outcome , Regional Blood Flow , Umbilical Arteries/physiopathology , Uterus/blood supply
SELECTION OF CITATIONS
SEARCH DETAIL
...